AzTrials
AzTrials

Functional ConstipationPhase 2NCT02314936

Dose-ranging Efficacy of Polydextrose Supplement on Colonic Transit Time and Symptoms in Adults With Functional Constipation

A Phase 2 study testing Litesse powder containing 12 g polydextrose, Litesse powder containing 8 g polydextrose and Litesse powder containing 4 g polydextrose in people with Functional Constipation, run by KGK Science Inc. at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study will investigate the effectiveness of Polydextrose, a dietary fiber, at decreasing Colonic Transit Time and the gastrointestinal symptoms of Functional Constipation. One quarter of the subjects will receive 12 g of Polydextrose daily, one quarter will receive 8 g of Polydextrose daily, one quarter will… Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Functional Constipation
What is being tested?
Litesse powder containing 12 g polydextrose, Litesse powder containing 8 g polydextrose and Litesse powder containing 4 g polydextrose
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
192 participants
Where
1 siteCanada
Study dates
Apr 2015to May 2016
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age between 18 and 70 years.
  • Body mass index between 18.5 and 29.9 kg/m2 (encompasses normal weight and overweight).
  • If female, subject is not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation).
  • OR
  • Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include:
  • Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System), Intrauterine devices, Double barrier method, Vasectomy of partner (shown successful as per appropriate follow-up), Tubal ligation, and Non-heterosexual lifestyle (same sex partner).
Show all 15Show fewer
  • Meets the Rome III criteria for functional constipation as follows: (Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis):
  • Must meet 2 or more of the following criteria:
  • Straining during at least 25% of defecations, Lumpy or hard stools in at least 25% of defecations, Sensation of incomplete evacuation for at least 25% of defecations, Sensation of anorectal obstruction/blockage for at least 25% of defecations, Manual maneuvers to facilitate at least 25% of defecations (e.g., digital evacuation, support of the pelvic floor)
  • Fewer than three defecations per week
  • Loose stools are rarely present without the use of laxatives
  • Insufficient criteria for irritable bowel syndrome
  • Ability of the participant (in the investigator's opinion) to comprehend the full nature and purpose of the study including possible risks and side effects.
  • Consent to the study and willing to comply with study product and methods.
  • Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research.

Who cannot join

  • Major gastrointestinal complication (e.g. Crohn's disease, colitis, celiac disease)
  • Prior abdominal surgery that in the opinion of the investigator may present a risk for the subject or confound study results.
  • Clinically significant underlying systemic illness that may preclude the participant's ability to complete the trial or that may confound the study outcomes (e.g. bowel cancer, prostate cancer, terminal illness).
  • Daily consumption of probiotics, prebiotics, fermented milk, and/or yogurt within 2 weeks of screening and throughout the trial other than the provided study products.
  • Laxative use within 48 hours of screening (rescue medication allowed for intolerable symptoms during study).
  • Regular use of any drug or dietary supplement known to cause constipation (e.g. iron, opioids, sucralfate, misoprostol, 5-HT#-antagonists, antacids with magnesium, calcium or aluminum, antidiarrheal medication, anticholinergic agents, calcium supplements, calcium channel blockers, tricyclic antidepressants or NSAIDs), within 1 month before screening.
Show all 16Show fewer
  • Anticipated major dietary or exercise changes during the study.
  • Systemic steroid use, within 1 month before screening.
  • Eating disorder.
  • Contraindication to dairy products (e.g., intolerance to lactose or any substance in the study product).
  • History of alcohol, drug, or medication abuse.
  • Pregnant or lactating female, or pregnancy planned during study period.
  • Participation in another study with any investigational product within 60 days of screening.
  • Investigator believes that the participant may be uncooperative and/or noncompliant and should therefore not participate in the study.
  • Subject under administrative or legal supervision.
  • Subject who would receive more than 4500 Euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study.

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • KGK Synergize Inc.

    London, Ontario, N6A 5R8

Other trials in Canada

About this study

Official title: Dose-ranging Efficacy of Supplementation With Polydextrose, a Dietary Fibre, on Colonic Transit Time and Gastrointestinal Symptoms in Adults With Functional Constipation: A Double-blind, Randomized, Placebo-controlled Trial

This study will investigate the effectiveness of Polydextrose, a dietary fiber, at decreasing Colonic Transit Time and the gastrointestinal symptoms of Functional Constipation. One quarter of the subjects will receive 12 g of Polydextrose daily, one quarter will receive 8 g of Polydextrose daily, one quarter will receive 4 g of Polydextrose daily and one quarter will receive a placebo daily.

Being tested
Litesse powder containing 12 g polydextrose, Litesse powder containing 8 g polydextrose, Litesse powder containing 4 g polydextrose, Placebo
Keywords
Constipation, Polydextrose, Dietary Fiber, PAC-QoL, Colonic Transit Time, PAC-SYM
Medical subject headings
Constipation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Litesse powder containing 12 g polydextroseDietary supplement

    Also called Litesse powder

    12 g polydextrose

  • Litesse powder containing 8 g polydextroseDietary supplement

    Also called Litesse powder

    8 g polydextrose, 4 g maltodextrin

  • Litesse powder containing 4 g polydextroseDietary supplement

    Also called Litesse powder

    4 g polydextrose, 8 g maltodextrin

  • PlaceboDietary supplement

    12 g Maltodextrin

Study groups in NCT02314936
Study groupRoleWhat they receive
Litesse powder containing 12 g polydextroseExperimental12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Receives: Dietary Supplement: Litesse powder containing 12 g polydextrose
Litesse powder containing 8 g polydextroseExperimental8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Receives: Dietary Supplement: Litesse powder containing 8 g polydextrose
Litesse powder containing 4 g polydextroseExperimental4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Receives: Dietary Supplement: Litesse powder containing 4 g polydextrose
PlaceboPlacebo comparatorMaltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
Receives: Dietary Supplement: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Colonic Transit Time From Baseline to Day 15

    Assessed using abdominal x-ray. Subjects will take 24 radiopaque markers for 6 consecutive days (144 radiopaque markers in total) immediately preceding the x-ray dates.

    Measured: Baseline and Day 15

Secondary outcomes (11)
  1. Change in Participant Assessment of Constipation Symptoms (PAC-SYM) From Baseline to Day 15

    Assessed using the PAC-SYM questionnaire (overall score, abdominal symptoms score, rectal symptoms score, and stool symptoms score).

    The PAC-SYM was developed as a brief, easily administered tool to assess symptom frequency and severity of chronic constipation. The authors used a definition for constipation was based on the Rome II criteria. This 12-item self-report measure is divided into the 3 symptom subscales of: abdominal, rectal and stool subscales.

    All items (sub-scores and the total score) are scored on a five-point Likert scale ranging from 0 (absence of symptom) to 4 (very severe) where lower scores are better. Scores for the total number of non-missing items within the subscale or total score are summed and divided by the total number of non-missing items for that subscale or total score.

    Measured: Baseline and Day 15

  2. Change in Participant Assessment of Constipation Quality of Life (PAC-QoL) From Baseline to Day 15

    Assessed using the PAC-QoL questionnaire (Overall Score, Worries and Concerns Score, Physical Discomfort Score, Psychosocial Discomfort Score, and Satisfaction Score)

    The Patient Assessment of Constipation (PAC) was developed to address the need for a disease-specific patient-reported outcomes measure. It includes components from complementary symptom and quality of life questionnaires.

    The PAC-QOL contains 28 items grouped into 4 subscales covering: worries and concerns (11 items), physical discomfort (4 items), psychosocial discomfort (8 items), and satisfaction (5 items).

    A 5-point Likert response scale, ranging from 0 (not at all / none of the time) to 4 (extremely / all of the time), where lower scores are better. Scores are computed as the average non-missing item response within the subscale where each score is given equal weight; the global score is calculated as the mean of the 28-items.

    Measured: Baseline and Day 15

  3. Change in Bowel Function Index From Baseline to Day 15

    Assessed using the Bowel Function Index questionnaire (total score, ease of defecation, feeling of incomplete bowel evacuation, and personal judgement of constipation).

    Each of the three questions used a numerical analog scale (0 = easy/no difficulty/not at all, 100 = very strong/very difficult) for grading purposes. The three questions were calculated as single scores as well as by a total score defined as the average of the three questions.

    Measured: Baseline and Day 15

  4. Change in Adequate Relief of Constipation Symptoms From Baseline to Day 15

    Assessed using single question dichotomous tool.

    Adequate relief quantified the difference in the number of participants experiencing relief from constipation between participants supplemented with Litesse and those supplemented with a placebo at baseline and day 14. The units of analysis for the relief questionnaire were the number of participants who reported relief from constipation.

    Measured: Baseline and Day 15

  5. Change in Stool Frequency From Baseline to Day 15

    Participants will record the number of defecations per day in a daily diary

    Measured: 14 day run-in and Week 2 of the 14-day supplementation period

  6. Change in Stool Consistency From Baseline to Day 15

    Stool consistency will be rated each day in a diary by using the Bristol Stool Scale Form.

    Bristol Stool Scale:

    The BSS is a categorical scale ranging from 1 to 7 that interprets the consistency of a single bowel movement; a single score is recorded and used for analysis. Lower scores are associated with hard and lumpy consistencies while higher scores are associated with soft or liquid consistencies. Generally, an optimal BSS scores ranges from 3 to 5.

    Measured: 14 day run-in and Week 2 of the 14-day supplementation period

  7. Change in the Degree of Straining During Defecation From Baseline to Day 15

    Degree of straining for each bowel movement will be recorded in a daily diary using a 5-point scale.

    The degree of straining is a rating scale ranging from 1 (not at al) to 5 (an extreme amount) that interprets the degree to which an individual must strain during a unique defecation; a single core is recorded and used for analysis. Scores were calculated as the weekly average of the daily degree of straining (1-5) where a lower score represented less straining.

    Measured: 14 day run-in and Week 2 of the 14-day supplementation period

  8. Change in the Sensation of Complete Bowel Emptying From Baseline to Day 15

    Sensation of complete bowel emptying for each bowel movement will be recorded in a daily diary on a dichotomous "yes" or "no" scale.

    The change in the sensation was defined as the change from baseline to week 2 in the percentage of complete bowel movements (CBMs) between participants supplemented with Litesse and those supplemented with a placebo. It assessed whether the participant felt as though their bowel movement was complete. The units of analysis for the sensation of complete bowel emptying was the weekly percentage of complete bowel movements, for each participant at run-in (week -1), week 1 and week 2.

    Measured: 14 day run-in and Week 2 of the 14-day supplementation period

  9. Change in the Severity of Abdominal Discomfort From Baseline to Day 15

    Severity of abdominal discomfort will be recorded each day in a daily diary on a 5-point scale.

    The severity of abdominal discomfort was calculated from a rating scale ranging from 1 (not at all) to 5 very severe); a single score was recorded and used for analysis. Scores were calculated as the weekly average of the daily degree of discomfort where a lower score represented less straining.

    Measured: 14 day run-in and Week 2 of the 14-day supplementation period

  10. Change in the Bloating Severity From Baseline to Day 15

    Severity of bloating will be recorded each day in a daily diary on a 5-point scale.

    The severity of abdominal bloating was calculated from a rating scale ranging from 1 (not at all) to 5 very severe); a single score was recorded and used for analysis. Scores were calculated as the weekly average of the daily degree of bloating where a lower score represented less straining.

    Measured: 14 day run-in and Week 2 of the 14-day supplementation period

  11. Overall Product Satisfaction

    Participants will be asked to rate their overall satisfaction with the study product's ability to relieve their constipation symptoms on a 5-point ordinal scale.

    The overall product satisfaction questionnaire consists of a single question that provides insight regarding the participants satisfaction on the product's ability to relieve constipation symptoms. The score that the participant indicates is considered the total score and no sub-scores are calculated. It is a rating scale that ranges from 1 (not at all satisfied) to 5 (very satisfied) where a higher score at the end-of-study indicates an improvement.

    Measured: Assessed at Day 15 (end of study)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Dec 2014 (estimated)
  2. Study startApr 2015
  3. Primary completionApr 2016
  4. Study completionMay 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
192 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02314936
Sponsor's protocol ID
01-2014
Status last verified
Apr 2018
First submitted
8 Dec 2014
Last updated
9 Nov 2018
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Litesse powder containing 12 g polydextrose, Litesse powder containing 8 g polydextrose and Litesse powder containing 4 g polydextrose in people with Functional Constipation, run by KGK Science Inc. at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 Nov 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Colonic Transit Time From Baseline to Day 15 (time frame: Baseline and Day 15). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in